Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00284-2/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsmi=297597675&_hsenc=p2ANqtz-8HmlCXwRR0c3Wt_091d6-QBhkId5Jemr39HSwEh3qDmP1G0OY23MoEG_CJE9QxwlVJpo65-qctSoKmXdhxVrwNgyOslg&utm_content=297411416&utm_source=hs_email